Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St Louis, MO 63104, USA.
Department of Pediatrics Residency, Washington University Medical School, St. Louis, MO 63105, USA.
Cells. 2020 Feb 8;9(2):395. doi: 10.3390/cells9020395.
Hutchinson-Gilford Progeria Syndrome (HGPS) is a segmental premature aging disease causing patient death by early teenage years from cardiovascular dysfunction. Although HGPS does not totally recapitulate normal aging, it does harbor many similarities to the normal aging process, with patients also developing cardiovascular disease, alopecia, bone and joint abnormalities, and adipose changes. It is unsurprising, then, that as physicians and scientists have searched for treatments for HGPS, they have targeted many pathways known to be involved in normal aging, including inflammation, DNA damage, epigenetic changes, and stem cell exhaustion. Although less studied at a mechanistic level, severe metabolic problems are observed in HGPS patients. Interestingly, new research in animal models of HGPS has demonstrated impressive lifespan improvements secondary to metabolic interventions. As such, further understanding metabolism, its contribution to HGPS, and its therapeutic potential has far-reaching ramifications for this disease still lacking a robust treatment strategy.
哈钦森-吉尔福德早衰综合征(Hutchinson-Gilford Progeria Syndrome,HGPS)是一种节段性过早衰老疾病,可导致患者在青少年早期因心血管功能障碍而死亡。尽管 HGPS 不能完全再现正常衰老,但它确实与正常衰老过程有许多相似之处,患者也会出现心血管疾病、脱发、骨骼和关节异常以及脂肪变化。因此,当医生和科学家寻找 HGPS 的治疗方法时,他们针对了许多已知与正常衰老过程相关的途径,包括炎症、DNA 损伤、表观遗传变化和干细胞衰竭。尽管在机制水平上研究较少,但 HGPS 患者存在严重的代谢问题。有趣的是,HGPS 动物模型的新研究表明,代谢干预可显著改善其寿命。因此,进一步了解代谢及其对 HGPS 的贡献及其治疗潜力,对这种仍然缺乏有效治疗策略的疾病具有深远的影响。